Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 May 12;3(2):dlab050. doi: 10.1093/jacamr/dlab050

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

PMC Copyright notice

Figure 1. — ADR survey: prevalence of HIVDR and DRMs in Maputo and Tete. HIVDR prevalence by ARV (a) was estimated from RT sequencing using Stanford HIV db v.8.4. Drug resistance levels reported for both study sites (b, c) were classified according to Stanford score (SS): Low-level resistance (SS: 15–29), Intermediate level resistance (SS: 30–59) and High-level resistance (SS ≥ 60). Frequency of DRMs (d) is reported by drug class. NRTIs: 3TC, lamivudine; FTC, emtricitabine; ABC, abacavir; ZDV, zidovudine; D4T, stavudine; DDI, didanosine; TDF, tenofovir. NNRTIs: EFV, efavirenz; NVP, nevirapine; RPV, rilpivirine; ETR, etravirine.